MG
HOWL icon

Michael Gelband’s Werewolf Therapeutics HOWL Stock Holding History

Michael Gelband’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,240
Closed -$164K – 1707
2024
Q1 		$164K Buy
+25,240
New +$147K ﹤0.01% 1379

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's HOWL Position: Q2 2024 in Review

Michael Gelband sold out of Werewolf Therapeutics (HOWL) in Q2 2024, closing a stake of 25,240 shares — an estimated $164K sold.

Michael Gelband first reported a position in HOWL in Q1 2024 and held it in 1 quarter. The position peaked at $164K in Q1 2024. 71 funds tracked by Wall St. Rank hold HOWL as of Q2 2024.

  • Michael Gelband reported no remaining Werewolf Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Michael Gelband sold 25,240 Werewolf Therapeutics shares in Q2 2024, an estimated $164K.
  • Michael Gelband first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 1 quarter.
  • Michael Gelband's Werewolf Therapeutics position peaked at $164K in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.